Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
1 hedge funds and large institutions have $0 invested in Repros Therapeutics Inc. in 2018 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 29 closing their positions.
97% less funds holding
Funds holding: 30 → 1 (-29)
100% less capital invested
Capital invested by funds: $3.33M → $0 (-$3.33M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 29
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$773K |
| 2 |
Renaissance Technologies
New York
|
-$525K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$486K |
| 4 |
BlackRock
New York
|
-$454K |
| 5 |
KAM
Kassirer Asset Management
Toronto,
Ontario, Canada
|
-$435K |
RPRX Hedge Fund Activity: Q1 2018 in Review
1 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q1 2018, worth a combined $0 — down 100% from $3.33M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of RPRX and 0 opened new positions — a net loss of 29 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Fidelity Investments, exiting entirely with an estimated $773K sold.
- 1 institutional investor held Repros Therapeutics Inc. (RPRX) as of Q1 2018, down from 30 in Q4 2017.
- Funds reported $0 of Repros Therapeutics Inc. stock for Q1 2018, down 100% quarter-over-quarter.
- 0 funds opened new Repros Therapeutics Inc. positions in Q1 2018 and 29 closed out, a net change of -29 holders.
- The largest Repros Therapeutics Inc. seller in Q1 2018 was Fidelity Investments, an estimated $773K sold.
Based on aggregated 13F filings for Q1 2018.